{
  "meta": {
    "title": "Approach_To_Lft_Hepatitis",
    "url": "https://brainandscalpel.vercel.app/approach-to-lft-hepatitis-566d11dc.html",
    "scrapedAt": "2025-11-29T18:24:48.792Z"
  },
  "questions": [
    {
      "id": 20173,
      "choices": [
        {
          "id": 80654,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated ALT, normal AST</span></span></span></p>"
        },
        {
          "id": 80655,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated AST, normal ALT</span></span></span></p>"
        },
        {
          "id": 80656,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated ALT and AST</span></span></span></p>"
        },
        {
          "id": 80657,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated alkaline phosphatase, normal ALT and AST</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following patterns of liver function tests (LFTs) is most consistent with acute viral hepatitis?</span></span></span></p>",
      "unique_key": "Q2021302",
      "question_audio": null,
      "question_video": null,
      "map_id": 20121,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Elevated ALT and AST</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In acute viral hepatitis, there is typically a marked elevation in both ALT and AST levels, reflecting hepatocellular injury. ALT is often higher than AST, but both enzymes are usually elevated. This pattern is consistent with liver cell necrosis and inflammation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Elevated ALT, normal AST</strong>: While elevated ALT is characteristic of hepatocellular injury, normal AST levels would be less typical in acute viral hepatitis where both enzymes are usually elevated.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Elevated AST, normal ALT</span></strong><span style=\"font-size:12.0pt\">: While elevated AST can indicate hepatocellular injury, normal ALT levels would be less consistent with acute viral hepatitis.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Elevated alkaline phosphatase, normal ALT and AST</span></strong><span style=\"font-size:12.0pt\">: This pattern is more suggestive of cholestatic liver disease rather than acute viral hepatitis, as alkaline phosphatase levels are typically elevated in cholestasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In acute viral hepatitis, both ALT and AST levels are typically elevated, reflecting hepatocellular injury. </span></span></span></p>",
      "correct_choice_id": 80656,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20174,
      "choices": [
        {
          "id": 80658,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated ALT, normal AST</span></span></span></p>"
        },
        {
          "id": 80659,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated AST, normal ALT</span></span></span></p>"
        },
        {
          "id": 80660,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated ALT and AST</span></span></span></p>"
        },
        {
          "id": 80661,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated alkaline phosphatase, normal ALT and AST</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following patterns of liver function tests (LFTs) is most consistent with ischemic hepatitis?</span></span></p>",
      "unique_key": "Q6169362",
      "question_audio": null,
      "question_video": null,
      "map_id": 20122,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Elevated ALT and AST</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ischemic hepatitis, also known as shock liver, typically presents with marked elevations in both ALT and AST levels, often exceeding 10 times the upper limit of normal. This pattern reflects acute hepatocellular injury due to compromised hepatic perfusion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Elevated ALT, normal AST</span></strong><span style=\"font-size:12.0pt\">: While elevated ALT is characteristic of hepatocellular injury, normal AST levels would be less typical in ischemic hepatitis, where both enzymes are usually elevated.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Elevated AST, normal ALT</span></strong><span style=\"font-size:12.0pt\">: While elevated AST can indicate hepatocellular injury, normal ALT levels would be less consistent with ischemic hepatitis.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Elevated alkaline phosphatase, normal ALT and AST</span></strong><span style=\"font-size:12.0pt\">: This pattern is more suggestive of cholestatic liver disease rather than ischemic hepatitis, as alkaline phosphatase levels are typically elevated in cholestasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ischemic hepatitis typically presents with marked elevations in both ALT and AST levels, reflecting acute hepatocellular injury due to compromised hepatic perfusion. </span></span></span></p>",
      "correct_choice_id": 80660,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20175,
      "choices": [
        {
          "id": 80662,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated ALT, normal AST</span></span></p>"
        },
        {
          "id": 80663,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated AST, normal ALT</span></span></p>"
        },
        {
          "id": 80664,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated ALT and AST</span></span></p>"
        },
        {
          "id": 80665,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated alkaline phosphatase, normal ALT and AST</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following patterns of liver function tests (LFTs) is most consistent with acute fulminant Wilson&#39;s disease?</span></span></p>",
      "unique_key": "Q5609954",
      "question_audio": null,
      "question_video": null,
      "map_id": 20123,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Elevated ALT and AST</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In acute fulminant Wilson&#39;s disease, both ALT and AST levels are typically elevated, reflecting severe hepatocellular injury and necrosis. This pattern of LFT abnormalities is consistent with acute liver failure in the setting of Wilson&#39;s disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option A. Elevated ALT, normal AST</strong>: While elevated ALT is characteristic of hepatocellular injury, normal AST levels would be less typical in acute fulminant Wilson&#39;s disease, where both enzymes are usually elevated.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Elevated AST, normal ALT</span></strong><span style=\"font-size:12.0pt\">: While elevated AST can indicate hepatocellular injury, normal ALT levels would be less consistent with acute fulminant Wilson&#39;s disease.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Elevated alkaline phosphatase, normal ALT and AST</span></strong><span style=\"font-size:12.0pt\">: This pattern is more suggestive of cholestatic liver disease rather than acute fulminant Wilson&#39;s disease, as alkaline phosphatase levels are typically elevated in cholestasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></strong></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute fulminant Wilson&#39;s disease presents with markedly elevated ALT and AST levels, reflecting severe hepatocellular injury and necrosis. </span></span></p>",
      "correct_choice_id": 80664,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20176,
      "choices": [
        {
          "id": 80666,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated ALT, normal AST</span></span></p>"
        },
        {
          "id": 80667,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated AST, normal ALT</span></span></p>"
        },
        {
          "id": 80668,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated ALT and AST</span></span></p>"
        },
        {
          "id": 80669,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated alkaline phosphatase, normal ALT and AST</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following patterns of liver function tests (LFTs) is most consistent with alcoholic hepatitis?</span></span></span></p>",
      "unique_key": "Q3112815",
      "question_audio": null,
      "question_video": null,
      "map_id": 20124,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Elevated ALT and AST</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alcoholic hepatitis typically presents with marked elevations in both ALT and AST levels, reflecting hepatocellular injury. The pattern of elevated ALT and AST is consistent with the hepatocellular inflammation seen in alcoholic hepatitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Elevated ALT, normal AST</span></strong><span style=\"font-size:12.0pt\">: While elevated ALT is characteristic of hepatocellular injury, normal AST levels would be less typical in alcoholic hepatitis, where both enzymes are usually elevated.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Elevated AST, normal ALT</span></strong><span style=\"font-size:12.0pt\">: While elevated AST can indicate hepatocellular injury, normal ALT levels would be less consistent with alcoholic hepatitis.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Elevated alkaline phosphatase, normal ALT and AST</span></strong><span style=\"font-size:12.0pt\">: This pattern is more suggestive of cholestatic liver disease rather than alcoholic hepatitis, as alkaline phosphatase levels are typically elevated in cholestasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alcoholic hepatitis typically presents with marked elevations in both ALT and AST levels, reflecting hepatocellular injury. </span></span></span></p>",
      "correct_choice_id": 80668,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20177,
      "choices": [
        {
          "id": 80670,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Child-Pugh score</span></span></p>"
        },
        {
          "id": 80671,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glasgow Alcoholic Hepatitis Score</span></span></p>"
        },
        {
          "id": 80672,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Maddrey&#39;s Discriminant Function</span></span></p>"
        },
        {
          "id": 80673,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MELD score</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following calculations is most appropriate to assess the severity and prognosis of alcoholic hepatitis?</span></span></p>",
      "unique_key": "Q8839134",
      "question_audio": null,
      "question_video": null,
      "map_id": 20125,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Maddrey&#39;s Discriminant Function</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Maddrey&#39;s Discriminant Function is calculated using the formula: (4.6 &times; [prothrombin time (seconds) - control]) + serum bilirubin (mg/dL). A value greater than 32 indicates severe alcoholic hepatitis and predicts mortality.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Child-Pugh score</span></strong><span style=\"font-size:12.0pt\">: While used to assess the severity of liver disease, the Child-Pugh score may not be as specific for alcoholic hepatitis severity as Maddrey&#39;s Discriminant Function.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Glasgow Alcoholic Hepatitis Score</span></strong><span style=\"font-size:12.0pt\">: This scoring system assesses the severity of alcoholic hepatitis but does not specifically incorporate INR, which is a component of Maddrey&#39;s Discriminant Function.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. MELD score</span></strong><span style=\"font-size:12.0pt\">: The Model for End-Stage Liver Disease (MELD) score is used for liver transplant allocation and does not specifically assess the severity of alcoholic hepatitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Maddrey&#39;s Discriminant Function is a valuable tool for assessing the severity and prognosis of alcoholic hepatitis, guiding treatment decisions and predicting mortality in patients with this condition.</span></span></span></p>",
      "correct_choice_id": 80672,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20178,
      "choices": [
        {
          "id": 80674,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prednisolone</span></span></p>"
        },
        {
          "id": 80675,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pentoxifylline</span></span></p>"
        },
        {
          "id": 80676,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">N-acetylcysteine (NAC)</span></span></p>"
        },
        {
          "id": 80677,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ursodeoxycholic acid (UDCA)</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the primary pharmacological treatment for severe alcoholic hepatitis?</span></span></p>",
      "unique_key": "Q2788010",
      "question_audio": null,
      "question_video": null,
      "map_id": 20126,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Prednisolone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Prednisolone is the primary pharmacological treatment for severe alcoholic hepatitis. It reduces inflammation and improves short-term survival, especially in patients with a Maddrey&#39;s Discriminant Function greater than 32.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Pentoxifylline</span></strong><span style=\"font-size:12.0pt\">: While also used in the management of severe alcoholic hepatitis, pentoxifylline has shown less efficacy compared to prednisolone in improving short-term survival.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. N-acetylcysteine (NAC)</span></strong><span style=\"font-size:12.0pt\">: NAC is primarily used for acetaminophen overdose and does not have a significant role in the treatment of alcoholic hepatitis.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Ursodeoxycholic acid (UDCA)</span></strong><span style=\"font-size:12.0pt\">: UDCA is not recommended for the treatment of alcoholic hepatitis as it may worsen outcomes in this condition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></strong></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prednisolone is the primary pharmacological treatment for severe alcoholic hepatitis, improving short-term survival by reducing inflammation. </span></span></p>",
      "correct_choice_id": 80674,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20179,
      "choices": [
        {
          "id": 80678,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-alcoholic fatty liver disease (NAFLD)</span></span></p>"
        },
        {
          "id": 80679,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alcoholic liver disease</span></span></p>"
        },
        {
          "id": 80680,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute viral hepatitis</span></span></p>"
        },
        {
          "id": 80681,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Autoimmune hepatitis</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old obese patient presents with fatigue, right upper quadrant abdominal pain, and hepatomegaly. Laboratory tests reveal elevated liver enzymes and imaging studies show hepatic steatosis. Which of the following is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q7160783",
      "question_audio": null,
      "question_video": null,
      "map_id": 20127,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Non-alcoholic fatty liver disease (NAFLD)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation of an obese patient with elevated liver enzymes, hepatomegaly, and hepatic steatosis on imaging is consistent with non-alcoholic fatty liver disease (NAFLD), which includes non-alcoholic steatohepatitis (NASH) as a progressive form.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Alcoholic liver disease</span></strong><span style=\"font-size:12.0pt\">: While alcohol consumption can also lead to fatty liver disease, the absence of significant alcohol intake in this patient makes NAFLD more likely.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Acute viral hepatitis</span></strong><span style=\"font-size:12.0pt\">: The clinical presentation and imaging findings are not consistent with acute viral hepatitis, which typically presents with acute onset jaundice and viral prodrome.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Autoimmune hepatitis</span></strong><span style=\"font-size:12.0pt\">: Although autoimmune hepatitis can present with elevated liver enzymes and hepatomegaly, the association with obesity and hepatic steatosis makes NAFLD more likely in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation and risk factors for NAFLD, including obesity and hepatic steatosis, aids in the diagnosis and management of non-alcoholic fatty liver disease, which encompasses non-alcoholic steatohepatitis (NASH) as a progressive form.</span></span></span></p>",
      "correct_choice_id": 80678,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20180,
      "choices": [
        {
          "id": 80682,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Presence of Mallory-Denk bodies</span></span></p>"
        },
        {
          "id": 80683,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Periportal inflammation</span></span></p>"
        },
        {
          "id": 80684,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bile duct proliferation</span></span></p>"
        },
        {
          "id": 80685,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hepatic iron deposition</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following histological findings is characteristic of non-alcoholic steatohepatitis (NASH)?</span></span></span></p>",
      "unique_key": "Q5872184",
      "question_audio": null,
      "question_video": null,
      "map_id": 20128,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Presence of Mallory-Denk bodies</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mallory-Denk bodies, which are intracytoplasmic eosinophilic inclusions in hepatocytes, are characteristic histological features of non-alcoholic steatohepatitis (NASH), indicating cellular injury and necrosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option B. Periportal inflammation</strong>: While inflammation is a feature of NASH, it typically involves the lobular region rather than periportal areas.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Bile duct proliferation</span></strong><span style=\"font-size:12.0pt\">: Bile duct proliferation is not a typical histological finding in NASH and is more suggestive of chronic cholestatic liver diseases.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hepatic iron deposition</span></strong><span style=\"font-size:12.0pt\">: Hepatic iron deposition is not a characteristic histological finding in NASH and is more commonly associated with hereditary hemochromatosis or chronic liver disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Characteristic histological features of NASH, such as Mallory-Denk bodies, helps in the accurate diagnosis and differentiation from other liver diseases, guiding appropriate management strategies.</span></span></span></p>",
      "correct_choice_id": 80682,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20181,
      "choices": [
        {
          "id": 80686,
          "text": "<p><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ursodeoxycholic acid (UDCA)</span></span></p>"
        },
        {
          "id": 80687,
          "text": "<p><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pioglitazone</span></span></p>"
        },
        {
          "id": 80688,
          "text": "<p><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metformin</span></span></p>"
        },
        {
          "id": 80689,
          "text": "<p><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin E</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the primary pharmacological treatment for NASH?</span></span></p>",
      "unique_key": "Q3271436",
      "question_audio": null,
      "question_video": null,
      "map_id": 20129,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Pioglitazone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pioglitazone, a thiazolidinedione, has been shown to improve liver histology and reduce liver enzymes in patients with NASH. It has been considered as a primary pharmacological treatment for NASH, particularly in patients with diabetes or insulin resistance.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ursodeoxycholic acid (UDCA)</span></strong><span style=\"font-size:12.0pt\">: UDCA has not shown consistent efficacy in treating NASH and is not recommended as a primary pharmacological treatment.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Metformin</span></strong><span style=\"font-size:12.0pt\">: While metformin may improve insulin sensitivity, its role in treating NASH is limited and controversial.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Vitamin E</span></strong><span style=\"font-size:12.0pt\">: Vitamin E has shown some benefit in improving liver histology in NASH patients without diabetes but is not considered a first-line treatment option.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NASH, such as pioglitazone, aids in the management of this progressive liver disease, particularly in patients with associated metabolic risk factors like diabetes or insulin resistance.</span></span></span></p>",
      "correct_choice_id": 80687,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20182,
      "choices": [
        {
          "id": 80690,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated ALT and AST</span></span></p>"
        },
        {
          "id": 80691,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated ALT, normal AST</span></span></p>"
        },
        {
          "id": 80692,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated ALP and GGT, normal ALT and AST</span></span></p>"
        },
        {
          "id": 80693,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated bilirubin, normal ALP and GGT</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following patterns of liver function tests (LFTs) is most consistent with cholestatic liver disease?</span></span></span></p>",
      "unique_key": "Q2603910",
      "question_audio": null,
      "question_video": null,
      "map_id": 20130,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Elevated ALP and GGT, normal ALT and AST</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cholestatic liver diseases, such as primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), typically present with elevated levels of alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT), reflecting impaired bile flow. Normal levels of ALT and AST suggest minimal hepatocellular injury.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Elevated ALT and AST</span></strong><span style=\"font-size:12.0pt\">: This pattern is more indicative of hepatocellular injury rather than cholestasis.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Elevated ALT, normal AST</span></strong><span style=\"font-size:12.0pt\">: Elevated ALT with normal AST levels is not characteristic of cholestatic liver diseases.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Elevated bilirubin, normal ALP and GGT</span></strong><span style=\"font-size:12.0pt\">: While elevated bilirubin can occur in cholestatic liver diseases, normal ALP and GGT levels are inconsistent with impaired bile flow.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></strong></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The characteristic pattern of elevated ALP and GGT levels with normal ALT and AST helps in distinguishing cholestatic liver diseases from other causes of liver dysfunction, guiding further diagnostic evaluation and management.</span></span></p>",
      "correct_choice_id": 80692,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20183,
      "choices": [
        {
          "id": 80694,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wilson&#39;s disease</span></span></p>"
        },
        {
          "id": 80695,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemolytic anemia</span></span></p>"
        },
        {
          "id": 80696,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gilbert Syndrome</span></span></p>"
        },
        {
          "id": 80697,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dubin-Johnson syndrome</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 20-year-old male presents with intermittent episodes of mild jaundice, particularly during periods of stress or fasting. Laboratory tests reveal unconjugated hyperbilirubinemia with normal liver function tests. Which of the following conditions is most likely responsible for the patient&#39;s presentation?</span></span></p>",
      "unique_key": "Q5419303",
      "question_audio": null,
      "question_video": null,
      "map_id": 20131,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Gilbert Syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Gilbert Syndrome is characterized by mild unconjugated hyperbilirubinemia due to decreased activity of the enzyme UDP-glucuronosyltransferase (UGT1A1), resulting in impaired bilirubin conjugation. Patients typically have normal liver function tests and may experience exacerbations of jaundice during periods of stress, fasting, or illness.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Wilson&#39;s disease</span></strong><span style=\"font-size:12.0pt\">: Wilson&#39;s disease presents with hepatic copper accumulation leading to liver dysfunction, neurological symptoms, and Kayser-Fleischer rings, which are not present in Gilbert Syndrome.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hemolytic anemia</span></strong><span style=\"font-size:12.0pt\">: Hemolytic anemia can cause unconjugated hyperbilirubinemia due to increased bilirubin production from hemolysis, but it is associated with abnormal liver function tests reflecting increased bilirubin turnover.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Dubin-Johnson syndrome</span></strong><span style=\"font-size:12.0pt\">: Dubin-Johnson syndrome is characterized by conjugated hyperbilirubinemia due to impaired bilirubin excretion into bile, resulting in darkly pigmented liver tissue, which is not seen in Gilbert Syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></strong></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The clinical presentation and laboratory findings of Gilbert Syndrome, includes unconjugated hyperbilirubinemia with normal liver function tests.</span></span></p>",
      "correct_choice_id": 80696,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20184,
      "choices": [
        {
          "id": 80698,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gilbert Syndrome</span></span></p>"
        },
        {
          "id": 80699,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemolytic anemia</span></span></p>"
        },
        {
          "id": 80700,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Crigler-Najjar Syndrome</span></span></p>"
        },
        {
          "id": 80701,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dubin-Johnson Syndrome</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 2-week-old neonate presents with severe jaundice since birth. Laboratory tests reveal markedly elevated unconjugated bilirubin levels without evidence of hemolysis or liver dysfunction. Which of the following conditions is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q6835157",
      "question_audio": null,
      "question_video": null,
      "map_id": 20132,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Crigler-Najjar Syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Crigler-Najjar Syndrome is a rare autosomal recessive disorder characterized by deficient activity of the enzyme UDP-glucuronosyltransferase (UGT1A1), leading to impaired bilirubin conjugation. This results in severe unconjugated hyperbilirubinemia without hemolysis or liver dysfunction. Crigler-Najjar Syndrome is divided into type 1, which is more severe and requires lifelong phototherapy or liver transplantation, and type 2, which is less severe.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Gilbert Syndrome</span></strong><span style=\"font-size:12.0pt\">: Gilbert Syndrome also presents with unconjugated hyperbilirubinemia but is milder and typically presents later in life.</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option B. Hemolytic anemia</strong>: Hemolytic anemia can cause unconjugated hyperbilirubinemia, but it is associated with evidence of hemolysis on laboratory tests, which is not present in Crigler-Najjar Syndrome.</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option D. Dubin-Johnson Syndrome</strong>: Dubin-Johnson Syndrome presents with conjugated hyperbilirubinemia and is characterized by darkly pigmented liver tissue, which is not seen in Crigler-Najjar Syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></strong></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The clinical presentation and laboratory findings of Crigler-Najjar Syndrome, includes severe unconjugated hyperbilirubinemia without evidence of hemolysis or liver dysfunction, is essential for early diagnosis and appropriate management, which may include phototherapy or liver transplantation.</span></span></p>",
      "correct_choice_id": 80700,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20185,
      "choices": [
        {
          "id": 80702,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gilbert Syndrome</span></span></p>"
        },
        {
          "id": 80703,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemolytic anemia</span></span></p>"
        },
        {
          "id": 80704,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Crigler-Najjar Syndrome</span></span></p>"
        },
        {
          "id": 80705,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dubin-Johnson Syndrome</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old female presents with chronic jaundice and dark-colored urine. Laboratory tests reveal elevated levels of conjugated bilirubin and normal liver function tests. Abdominal imaging shows a liver with a characteristic &quot;black liver&quot; appearance. Which of the following conditions is the most likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-115621.jpg\" style=\"height:227px; width:400px\" /></span></span></p>",
      "unique_key": "Q2277063",
      "question_audio": null,
      "question_video": null,
      "map_id": 20133,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Dubin-Johnson Syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dubin-Johnson Syndrome is a rare autosomal recessive disorder characterized by defective hepatobiliary transport protein (MRP2) leading to impaired excretion of conjugated bilirubin into bile. This results in conjugated hyperbilirubinemia without liver dysfunction, giving the liver a characteristic black appearance on imaging due to pigment deposition</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Gilbert Syndrome</span></strong><span style=\"font-size:12.0pt\">: Gilbert Syndrome presents with unconjugated hyperbilirubinemia due to reduced activity of UDP-glucuronosyltransferase (UGT1A1), without evidence of liver dysfunction or bile pigment deposition.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hemolytic anemia</span></strong><span style=\"font-size:12.0pt\">: Hemolytic anemia can cause unconjugated hyperbilirubinemia due to increased bilirubin production from hemolysis, but it is not associated with conjugated hyperbilirubinemia or liver pigment deposition.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Crigler-Najjar Syndrome</span></strong><span style=\"font-size:12.0pt\">: Crigler-Najjar Syndrome is characterized by unconjugated hyperbilirubinemia due to deficient activity of UDP-glucuronosyltransferase (UGT1A1), without evidence of liver pigment deposition.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation and characteristic imaging findings of Dubin-Johnson Syndrome, including conjugated hyperbilirubinemia and a &quot;black liver&quot; appearance, aids in accurate diagnosis and differentiation from other causes of jaundice.</span></span></span></p>",
      "correct_choice_id": 80705,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20186,
      "choices": [
        {
          "id": 80706,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gilbert Syndrome</span></span></p>"
        },
        {
          "id": 80707,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemolytic anemia</span></span></p>"
        },
        {
          "id": 80708,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Crigler-Najjar Syndrome</span></span></p>"
        },
        {
          "id": 80709,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rotor Syndrome</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old male presents with chronic jaundice and dark urine with elevated levels of conjugated bilirubin with normal liver function tests. Abdominal imaging shows no abnormalities. Which of the following conditions is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q5069951",
      "question_audio": null,
      "question_video": null,
      "map_id": 20134,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Rotor Syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rotor Syndrome is a rare autosomal recessive disorder characterized by benign conjugated hyperbilirubinemia due to impaired hepatic uptake and excretion of bilirubin. Unlike Dubin-Johnson Syndrome, there is no black liver appearance on imaging. Liver function tests are typically normal in Rotor Syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Gilbert Syndrome</span></strong><span style=\"font-size:12.0pt\">: Gilbert Syndrome presents with unconjugated hyperbilirubinemia due to reduced activity of UDP-glucuronosyltransferase (UGT1A1), with normal liver function tests and no evidence of conjugated hyperbilirubinemia.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hemolytic anemia</span></strong><span style=\"font-size:12.0pt\">: Hemolytic anemia can cause unconjugated hyperbilirubinemia due to increased bilirubin production from hemolysis, but it is not associated with conjugated hyperbilirubinemia.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Crigler-Najjar Syndrome</span></strong><span style=\"font-size:12.0pt\">: Crigler-Najjar Syndrome is characterized by severe unconjugated hyperbilirubinemia due to deficient activity of UDP-glucuronosyltransferase (UGT1A1), with normal liver function tests and no evidence of conjugated hyperbilirubinemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation and laboratory findings of Rotor Syndrome, includes conjugated hyperbilirubinemia with normal liver function tests and absence of liver imaging abnormalities.</span></span></span></p>",
      "correct_choice_id": 80709,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20187,
      "choices": [
        {
          "id": 80710,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wilson&#39;s disease</span></span></p>"
        },
        {
          "id": 80711,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alagille syndrome</span></span></p>"
        },
        {
          "id": 80712,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Crigler-Najjar syndrome</span></span></p>"
        },
        {
          "id": 80713,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Progressive familial intrahepatic cholestasis (PFIC)</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 6-month-old infant presents with persistent jaundice, hepatosplenomegaly, and failure to thrive. Laboratory tests reveal elevated levels of conjugated bilirubin and liver function tests consistent with cholestasis. Abdominal imaging shows no abnormalities. Which of the following conditions is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q2231757",
      "question_audio": null,
      "question_video": null,
      "map_id": 20135,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Progressive familial intrahepatic cholestasis (PFIC)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">PFIC is a group of rare genetic disorders characterized by impaired bile flow due to defects in hepatobiliary transport proteins, leading to cholestasis. Infants typically present with jaundice, hepatosplenomegaly, and failure to thrive, along with elevated conjugated bilirubin levels and normal or mildly abnormal liver function tests. Imaging studies may appear normal initially.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Wilson&#39;s disease</span></strong><span style=\"font-size:12.0pt\">: Wilson&#39;s disease presents with hepatic copper accumulation leading to liver dysfunction and neurological symptoms, which are not typical features of PFIC.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Alagille syndrome</span></strong><span style=\"font-size:12.0pt\">: Alagille syndrome presents with bile duct paucity, characteristic facial features, and cardiac abnormalities, which are not features of PFIC.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Crigler-Najjar syndrome</span></strong><span style=\"font-size:12.0pt\">: Crigler-Najjar syndrome is characterized by unconjugated hyperbilirubinemia due to deficient activity of UDP-glucuronosyltransferase (UGT1A1), which is different from the cholestatic presentation seen in PFIC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation and laboratory findings of progressive familial intrahepatic cholestasis (PFIC), includes cholestasis with elevated conjugated bilirubin levels and normal or mildly abnormal liver function tests.</span></span></span></p>",
      "correct_choice_id": 80713,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20188,
      "choices": [
        {
          "id": 80714,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wilson&#39;s disease</span></span></p>"
        },
        {
          "id": 80715,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Progressive familial intrahepatic cholestasis (PFIC)</span></span></p>"
        },
        {
          "id": 80716,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Crigler-Najjar syndrome</span></span></p>"
        },
        {
          "id": 80717,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alagille syndrome</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 4-year-old child presents with jaundice, pruritus, cardiac murmur and characteristic facial features as below. Laboratory tests show elevated levels of conjugated bilirubin and liver function tests consistent with cholestasis. Which of the following conditions is the most likely diagnosis?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-130600.jpg\" style=\"height:444px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q8081777",
      "question_audio": null,
      "question_video": null,
      "map_id": 20136,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Alagille syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alagille syndrome is a genetic disorder characterized by bile duct paucity, leading to cholestasis. It presents with jaundice, pruritus, and characteristic facial features including a prominent forehead, deep-set eyes, and a pointed chin. Cardiac abnormalities, such as a murmur due to peripheral pulmonary stenosis, are common.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-130600_Lr5LzCE.jpg\" style=\"height:444px; width:300px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Wilson&#39;s disease</span></strong><span style=\"font-size:12.0pt\">: Wilson&#39;s disease presents with hepatic copper accumulation leading to liver dysfunction and neurological symptoms, which are not typical features of Alagille syndrome.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Progressive familial intrahepatic cholestasis (PFIC)</span></strong><span style=\"font-size:12.0pt\">: PFIC is characterized by defects in hepatobiliary transport proteins, leading to cholestasis, but it does not typically present with the characteristic facial features seen in Alagille syndrome.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Crigler-Najjar syndrome</span></strong><span style=\"font-size:12.0pt\">: Crigler-Najjar syndrome is characterized by unconjugated hyperbilirubinemia due to deficient activity of UDP-glucuronosyltransferase (UGT1A1), which is different from the cholestatic presentation seen in Alagille syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></strong></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The clinical presentation and characteristic facial features of Alagille syndrome, along with laboratory findings consistent with cholestasis.</span></span></p>",
      "correct_choice_id": 80717,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20189,
      "choices": [
        {
          "id": 80718,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic liver cirrhosis</span></span></p>"
        },
        {
          "id": 80719,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hepatocellular carcinoma</span></span></p>"
        },
        {
          "id": 80720,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fulminant hepatic failure</span></span></p>"
        },
        {
          "id": 80721,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic hepatitis B infection</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following manifestations is a rare but severe complication most likely associated with acute hepatitis B infection?</span></span></p>",
      "unique_key": "Q8545369",
      "question_audio": null,
      "question_video": null,
      "map_id": 20137,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Fulminant hepatic failure</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fulminant hepatic failure is a rare but severe complication of acute hepatitis B infection. It is characterized by rapid onset of liver failure, often leading to encephalopathy and coagulopathy within a short period.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chronic liver cirrhosis</span></strong><span style=\"font-size:12.0pt\">: Chronic liver cirrhosis is a long-term complication of chronic hepatitis B infection, not typically seen in the acute phase.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Hepatocellular carcinoma</span></strong><span style=\"font-size:12.0pt\">: Hepatocellular carcinoma is a long-term complication of chronic hepatitis B infection and is not associated with the acute phase of the disease.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Chronic hepatitis B infection</span></strong><span style=\"font-size:12.0pt\">: Chronic hepatitis B infection is characterized by persistent HBsAg positivity for more than six months and is not typically associated with acute manifestations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The manifestations of acute hepatitis B infection, includes fulminant hepatic failure which is a severe complication, aids in prompt diagnosis and management, preventing progression to life-threatening complications.</span></span></span></p>",
      "correct_choice_id": 80720,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20190,
      "choices": [
        {
          "id": 80722,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immune tolerance phase</span></span></p>"
        },
        {
          "id": 80723,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immune clearance phase</span></span></p>"
        },
        {
          "id": 80724,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immune control phase</span></span></p>"
        },
        {
          "id": 80725,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immune escape phase</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old female presents for routine health screening. Laboratory tests reveal positive serology for hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg), with elevated liver enzymes. Which of the following best describes the patient&#39;s hepatitis B virus (HBV) infection status?</span></span></p>",
      "unique_key": "Q2985444",
      "question_audio": null,
      "question_video": null,
      "map_id": 20138,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Immune clearance phase</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In the immune clearance phase, patients have active viral replication, elevated liver enzymes, and positive HBeAg. This phase is characterized by immune-mediated hepatocellular injury aimed at clearing the virus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Immune tolerance phase</span></strong><span style=\"font-size:12.0pt\">: In the immune tolerance phase, patients have high viral loads, normal liver enzymes, and positive HBeAg. There is minimal liver inflammation despite active viral replication.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Immune control phase</span></strong><span style=\"font-size:12.0pt\">: In the immune control phase, patients have low viral loads, normal liver enzymes, and negative HBeAg. There is minimal liver inflammation due to effective immune control of the virus.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Immune escape phase</span></strong><span style=\"font-size:12.0pt\">: The immune escape phase refers to the development of HBV mutants that evade immune recognition, typically occurring in chronic infection and associated with disease progression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></strong></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The different phases of hepatitis B virus (HBV) infection, includes the immune clearance phase characterized by active viral replication and elevated liver enzymes.</span></span></p>",
      "correct_choice_id": 80723,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20191,
      "choices": [
        {
          "id": 80726,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic hepatitis B infection</span></span></p>"
        },
        {
          "id": 80727,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute hepatitis B infection</span></span></p>"
        },
        {
          "id": 80728,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immune control phase</span></span></p>"
        },
        {
          "id": 80729,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Resolved hepatitis B infection</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following best describes a patient&#39;s hepatitis B virus (HBV) infection status if he has positive serology for hepatitis B surface antigen (HBsAg) , who has come for a routine check up ?</span></span></p>",
      "unique_key": "Q5455844",
      "question_audio": null,
      "question_video": null,
      "map_id": 20139,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Chronic hepatitis B infection</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Positive HBsAg indicates active hepatitis B virus (HBV) infection. In the absence of seroconversion within six months, it is classified as chronic hepatitis B infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Acute hepatitis B infection</span></strong><span style=\"font-size:12.0pt\">: Acute infection is characterized by the presence of HBsAg along with other markers such as IgM anti-HBc and HBV DNA.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Immune control phase</span></strong><span style=\"font-size:12.0pt\">: Immune control phase is characterized by low viral load, normal liver enzymes, and negative HBeAg.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Resolved hepatitis B infection</span></strong><span style=\"font-size:12.0pt\">: Resolved infection is characterized by the presence of anti-HBs and absence of HBsAg.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HBsAg positivity indicates chronic hepatitis B infection that helps in appropriate management and monitoring of patients.</span></span></span></p>",
      "correct_choice_id": 80726,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20192,
      "choices": [
        {
          "id": 80730,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic hepatitis B infection</span></span></p>"
        },
        {
          "id": 80731,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute hepatitis B infection</span></span></p>"
        },
        {
          "id": 80732,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immune control phase</span></span></p>"
        },
        {
          "id": 80733,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Resolved hepatitis B infection</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following best describes the patient&#39;s hepatitis B virus (HBV) infection status if she has positive serology for anti-HBs?</span></span></span></p>",
      "unique_key": "Q2822997",
      "question_audio": null,
      "question_video": null,
      "map_id": 20140,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Resolved hepatitis B infection</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Positive anti-HBs indicates immunity to hepatitis B, either through vaccination or resolution of natural infection. In the absence of HBsAg, it suggests resolved infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chronic hepatitis B infection</span></strong><span style=\"font-size:12.0pt\">: Chronic infection is characterized by persistent HBsAg positivity.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Acute hepatitis B infection</span></strong><span style=\"font-size:12.0pt\">: Acute infection is characterized by the presence of HBsAg, often accompanied by IgM anti-HBc.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Immune control phase</span></strong><span style=\"font-size:12.0pt\">: Immune control phase is characterized by low viral load, normal liver enzymes, and negative HBeAg.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-HBs positivity helps in indicating resolved hepatitis B infection or immunity from vaccination.</span></span></span></p>",
      "correct_choice_id": 80733,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20193,
      "choices": [
        {
          "id": 80734,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immune tolerance phase</span></span></p>"
        },
        {
          "id": 80735,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immune clearance phase</span></span></p>"
        },
        {
          "id": 80736,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immune control phase</span></span></p>"
        },
        {
          "id": 80737,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immune escape phase</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following best describes the patient&#39;s hepatitis B virus (HBV) infection status if patient shows positive serology for hepatitis B e antigen (HBeAg) ?</span></span></p>",
      "unique_key": "Q5127998",
      "question_audio": null,
      "question_video": null,
      "map_id": 20141,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Immune tolerance phase</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Presence of HBeAg, high viral load, and normal liver enzymes characterize the immune tolerance phase, where there is minimal liver inflammation despite active viral replication.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Immune clearance phase</span></strong><span style=\"font-size:12.0pt\">: In the immune clearance phase, patients have high viral loads, elevated liver enzymes, and positive HBeAg.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Immune control phase</span></strong><span style=\"font-size:12.0pt\">: In the immune control phase, patients have low viral loads, normal liver enzymes, and negative HBeAg.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Immune escape phase</span></strong><span style=\"font-size:12.0pt\">: The immune escape phase refers to the development of HBV mutants that evade immune recognition, typically occurring in chronic infection and associated with disease progression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The significance of HBeAg positivity helps in indicating the immune tolerance phase of hepatitis B infection </span></span></span></p>",
      "correct_choice_id": 80734,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20194,
      "choices": [
        {
          "id": 80738,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic hepatitis B infection</span></span></p>"
        },
        {
          "id": 80739,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute hepatitis B infection</span></span></p>"
        },
        {
          "id": 80740,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immune control phase</span></span></p>"
        },
        {
          "id": 80741,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Resolved hepatitis B infection</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following best describes the patient&#39;s hepatitis B virus (HBV) infection status if laboratory tests reveal positive serology for IgM antibodies to hepatitis B core antigen (anti-HBc IgM)?</span></span></p>",
      "unique_key": "Q9188758",
      "question_audio": null,
      "question_video": null,
      "map_id": 20142,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Acute hepatitis B infection</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Presence of IgM antibodies to hepatitis B core antigen (anti-HBc IgM) indicates acute infection with hepatitis B virus (HBV), typically within the window period before seroconversion of other markers.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chronic hepatitis B infection</span></strong><span style=\"font-size:12.0pt\">: Chronic infection is characterized by persistent HBsAg positivity and absence of IgM anti-HBc.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Immune control phase</span></strong><span style=\"font-size:12.0pt\">: Immune control phase is characterized by low viral load, normal liver enzymes, and negative anti-HBc IgM.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Resolved hepatitis B infection</span></strong><span style=\"font-size:12.0pt\">: Resolved infection is characterized by the presence of anti-HBs and absence of HBsAg and IgM anti-HBc.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IgM anti-HBc positivity indicates acute hepatitis B infection that aids in prompt diagnosis and management of patients presenting with acute hepatitis symptoms.</span></span></span></p>",
      "correct_choice_id": 80739,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20195,
      "choices": [
        {
          "id": 80742,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immune tolerance phase</span></span></p>"
        },
        {
          "id": 80743,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immune clearance phase</span></span></p>"
        },
        {
          "id": 80744,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immune control phase</span></span></p>"
        },
        {
          "id": 80745,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immune escape phase</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following best describes the patient&#39;s hepatitis B virus (HBV) infection status in a patient with chronic Hepatitis B infection and positive serology for antibodies to hepatitis B e antigen (anti-HBe)?</span></span></p>",
      "unique_key": "Q9012839",
      "question_audio": null,
      "question_video": null,
      "map_id": 20143,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Immune control phase</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Presence of antibodies to hepatitis B e antigen (anti-HBe) along with low viral load and normal liver enzymes indicates the immune control phase, where the immune system effectively suppresses viral replication.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Immune tolerance phase</span></strong><span style=\"font-size:12.0pt\">: In the immune tolerance phase, patients have high viral loads, normal liver enzymes, and positive HBeAg.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Immune clearance phase</span></strong><span style=\"font-size:12.0pt\">: In the immune clearance phase, patients have high viral loads, elevated liver enzymes, and positive HBeAg.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Immune escape phase</span></strong><span style=\"font-size:12.0pt\">: The immune escape phase refers to the development of HBV mutants that evade immune recognition, typically occurring in chronic infection and associated with disease progression.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anti-HBe positivity indicates the immune control phase of hepatitis B infection that helps in understanding disease progression and guiding management strategies for patients with chronic hepatitis B.</span></span></span></p>",
      "correct_choice_id": 80744,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20197,
      "choices": [
        {
          "id": 80750,
          "text": "<p><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lamivudine</span></span></p>"
        },
        {
          "id": 80751,
          "text": "<p><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Interferon-alpha</span></span></p>"
        },
        {
          "id": 80752,
          "text": "<p><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tenofovir disoproxil fumarate (TDF)</span></span></p>"
        },
        {
          "id": 80753,
          "text": "<p><span dir=\"ltr\" lang=\"IT\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adefovir dipivoxil</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old patient with chronic hepatitis B infection presents with elevated liver enzymes and detectable HBV DNA levels. The patient has no evidence of cirrhosis or hepatocellular carcinoma. Which of the following is the most appropriate initial treatment according to current guidelines?</span></span></span></p>",
      "unique_key": "Q8781233",
      "question_audio": null,
      "question_video": null,
      "map_id": 20145,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">C) Tenofovir disoproxil fumarate (TDF)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Current guidelines recommend nucleos(t)ide analogs such as tenofovir disoproxil fumarate (TDF) or entecavir as the first-line treatment for chronic hepatitis B infection due to their potent antiviral activity and low rates of resistance development.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Lamivudine</span></strong><span style=\"font-size:12.0pt\">: Lamivudine is an older nucleoside analog and is associated with high rates of resistance, making it a less preferred option for initial treatment.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Interferon-alpha</span></strong><span style=\"font-size:12.0pt\">: Interferon-alpha is less commonly used due to its side effect profile and limited efficacy compared to nucleos(t)ide analogs.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Adefovir dipivoxil</span></strong><span style=\"font-size:12.0pt\">: Adefovir dipivoxil is another nucleotide analog, but it is associated with a higher rate of nephrotoxicity and resistance compared to TDF or entecavir.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></strong></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The current treatment guidelines for chronic hepatitis B infection, includes the preference for nucleos(t)ide analogs such as tenofovir disoproxil fumarate (TDF) or entecavir as initial therapy that aids in appropriate management and prevention of disease progression.</span></span></p>",
      "correct_choice_id": 80752,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20199,
      "choices": [
        {
          "id": 80758,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Every 6 months</span></span></p>"
        },
        {
          "id": 80759,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Every 12 months</span></span></p>"
        },
        {
          "id": 80760,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Every 3 months</span></span></p>"
        },
        {
          "id": 80761,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Every 2 weeks</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the most appropriate interval for monitoring liver function tests and viral load during tenofovir disoproxil fumarate (TDF) therapy for chronic hepatitis B infection?</span></span></p>",
      "unique_key": "Q1023422",
      "question_audio": null,
      "question_video": null,
      "map_id": 20147,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Every 3 months</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Patients on antiviral therapy for chronic hepatitis B infection should undergo regular monitoring every 3 months to assess liver function tests, HBV DNA levels, and any signs of drug toxicity or resistance development.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Every 6 months</span></strong><span style=\"font-size:12.0pt\">: Monitoring every 6 months may not be frequent enough to detect changes in viral load or liver function tests in patients receiving antiviral therapy for chronic hepatitis B infection.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Every 12 months</span></strong><span style=\"font-size:12.0pt\">: Monitoring every 12 months is too infrequent for patients on antiviral therapy, as changes in viral load or liver function may occur earlier and require intervention.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Every 2 weeks</span></strong><span style=\"font-size:12.0pt\">: Monitoring every 2 weeks is too frequent and may not be necessary for stable patients on antiviral therapy for chronic hepatitis B infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The appropriate monitoring intervals for patients on antiviral therapy for chronic hepatitis B infection, includes regular assessments of liver function tests and viral load every 3 months and ensuring effective management and timely adjustment of treatment as needed.</span></span></span></p>",
      "correct_choice_id": 80760,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20200,
      "choices": [
        {
          "id": 80762,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HCV RNA PCR</span></span></p>"
        },
        {
          "id": 80763,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HCV core antigen assay</span></span></p>"
        },
        {
          "id": 80764,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HCV genotyping</span></span></p>"
        },
        {
          "id": 81853,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liver biopsy</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following are confirmatory tests for active HCV infection?</span></span></span></p>",
      "unique_key": "Q7415276",
      "question_audio": null,
      "question_video": null,
      "map_id": 20148,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) HCV RNA PCR</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HCV RNA PCR (Polymerase Chain Reaction) testing is the confirmatory test of choice to detect active HCV infection. It directly measures the presence of HCV RNA in the blood, indicating that the virus is currently replicating. This test is used to confirm active infection in patients who have tested positive for anti-HCV antibodies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong><span style=\"font-size:12.0pt\"> The HCV core antigen assay can be used as an alternative to HCV RNA PCR in some cases to confirm active infection, but HCV RNA PCR remains the gold standard for confirming active HCV replication.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> HCV genotyping is important for determining the genotype of the HCV virus, which can influence treatment decisions. However, it is not the initial confirmatory test for active infection; it is typically done after confirming active infection with HCV RNA PCR.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Liver biopsy is an invasive procedure used to assess liver damage and is not used as a confirmatory test for active HCV infection. It may be used in certain clinical scenarios to assess the extent of liver fibrosis or cirrhosis but is not necessary for the initial diagnosis of HCV.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">HCV RNA PCR is the confirmatory test for active infection following positive anti-HCV antibody serology that aids in accurate diagnosis and appropriate management.</span></span></span></p>",
      "correct_choice_id": 80762,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20201,
      "choices": [
        {
          "id": 80765,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute HCV infection</span></span></p>"
        },
        {
          "id": 80766,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic HCV infection</span></span></p>"
        },
        {
          "id": 80767,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Resolved HCV infection</span></span></p>"
        },
        {
          "id": 80768,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Reinfection with HCV</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old patient with a history of blood transfusion 20 years ago tests positive for anti-HCV antibodies and elevated liver enzymes. Which of the following best describes the patient&#39;s HCV infection status?</span></span></p>",
      "unique_key": "Q1593407",
      "question_audio": null,
      "question_video": null,
      "map_id": 20150,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Chronic HCV infection</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of positive serology for anti-HCV antibodies along with elevated liver enzymes in a patient with a risk factor (history of blood transfusion 20 years ago) is suggestive of chronic HCV infection. Chronic HCV infection is defined by the persistence of the virus for more than 6 months. Elevated liver enzymes indicate ongoing liver inflammation, which is common in chronic HCV infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Acute HCV infection typically refers to the initial 6 months following exposure to the virus. The history of a blood transfusion 20 years ago and the current presentation suggest a time frame beyond the acute phase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> Resolved HCV infection would be suggested by the presence of anti-HCV antibodies without detectable viral RNA and without elevated liver enzymes, indicating that the patient&#39;s immune system cleared the infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Reinfection with HCV implies that the patient had previously cleared the virus (either spontaneously or with treatment) and then was exposed to the virus again. This scenario would also require evidence of viral RNA to confirm ongoing infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of anti-HCV antibodies along with elevated liver enzymes in a patient with a risk factor for HCV exposure suggests chronic HCV infection, particularly when the exposure occurred more than 6 months prior.</span></span></span></p>",
      "correct_choice_id": 80766,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20203,
      "choices": [
        {
          "id": 80773,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-HCV antibodies indicate active HCV infection</span></span></p>"
        },
        {
          "id": 80774,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HCV RNA PCR is not necessary if anti-HCV antibodies are positive</span></span></p>"
        },
        {
          "id": 80775,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Resolved HCV infection is characterized by positive HCV RNA PCR</span></span></p>"
        },
        {
          "id": 80776,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HCV core antigen assay is used to detect prior HCV exposure</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old patient presents tests positive for anti-HCV antibodies and elevated liver enzymes. Which of the following statements regarding HCV serology is correct?</span></span></p>",
      "unique_key": "Q9995401",
      "question_audio": null,
      "question_video": null,
      "map_id": 20151,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) HCV core antigen assay is used to detect prior HCV exposure</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The HCV core antigen assay detects the presence of HCV core protein in the blood and is used as an alternative to anti-HCV antibody testing for detecting prior HCV exposure. Positive anti-HCV antibodies indicate past or current HCV infection but do not distinguish between resolved and chronic infection. HCV RNA PCR is necessary to confirm active infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Anti-HCV antibodies indicate exposure to the HCV virus but do not differentiate between active and resolved infections. The presence of antibodies alone cannot confirm active HCV infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B</span></strong><span style=\"font-size:12.0pt\">. HCV RNA PCR testing is necessary to confirm active HCV infection even if anti-HCV antibodies are positive. This is because anti-HCV antibodies can be present in both active and resolved infections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> Resolved HCV infection is characterized by the presence of anti-HCV antibodies without detectable HCV RNA. The absence of HCV RNA indicates that the virus is not currently replicating in the patient&#39;s body.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></strong></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HCV core antigen assay helps to detect prior HCV exposure, that aids in accurate diagnosis and management of hepatitis C virus (HCV) infection.</span></span></p>",
      "correct_choice_id": 80776,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20204,
      "choices": [
        {
          "id": 80777,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Initiate treatment with pegylated interferon and ribavirin </span></span></span></p>"
        },
        {
          "id": 80778,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Perform a liver biopsy to assess the degree of liver fibrosis </span></span></span></p>"
        },
        {
          "id": 80779,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Start direct-acting antiviral (DAA) therapy </span></span></span></p>"
        },
        {
          "id": 80780,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Recommend abstinence from alcohol and re-evaluate in 6 months</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old man with history of intravenous drug use tests positive for anti-HCV antibodies and a confirmatory HCV RNA PCR test indicates active infection. Genotyping shows genotype 1a HCV. His liver function tests are mildly elevated. There is no evidence of cirrhosis on imaging. What is the most appropriate next step in managing this patient&#39;s HCV infection?</span></span></span></p>",
      "unique_key": "Q9945427",
      "question_audio": null,
      "question_video": null,
      "map_id": 20152,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>C) Start direct-acting antiviral (DAA) therapy</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The current standard of care for chronic HCV infection, regardless of genotype, is treatment with direct-acting antivirals (DAAs). These medications have high cure rates, are well-tolerated, and have a short treatment duration, typically 8-12 weeks. This approach is recommended over older therapies like pegylated interferon and ribavirin due to better efficacy, fewer side effects, and a shorter duration of treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Pegylated interferon and ribavirin were used in the past but are now largely replaced by DAAs due to the latter&#39;s superior efficacy and safety profile.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong><span style=\"font-size:12.0pt\"> Liver biopsy to assess fibrosis is less commonly performed now due to the availability of non-invasive methods for assessing liver damage and the universal treatment recommendation for HCV regardless of fibrosis stage.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> While recommending abstinence from alcohol is important for liver health, it is not a substitute for antiviral treatment in patients with active HCV infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The management of chronic HCV infection with direct-acting antivirals is the standard of care. It emphasizes the shift away from older treatments like pegylated interferon and ribavirin to DAAs, which offer better efficacy, safety, and a shorter treatment duration.</span></span></span></p>",
      "correct_choice_id": 80779,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20209,
      "choices": [
        {
          "id": 80797,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ledipasvir/Sofosbuvir for 12 weeks </span></span></span></p>"
        },
        {
          "id": 80798,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sofosbuvir/Velpatasvir for 12 weeks </span></span></span></p>"
        },
        {
          "id": 80799,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elbasvir/Grazoprevir for 12 weeks</span></span></span></p>"
        },
        {
          "id": 80800,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sofosbuvir and ribavirin for 24 weeks</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For<strong>&nbsp;</strong></span><span style=\"font-size:12.0pt\">a 55-year-old female with chronic HCV infection genotype 2, without cirrhosis, what is the most appropriate treatment regimen?</span></span></span></p>",
      "unique_key": "Q4433661",
      "question_audio": null,
      "question_video": null,
      "map_id": 20157,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Ans.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>B) Sofosbuvir/Velpatasvir for 12 weeks</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For patients with HCV genotype 2 infection without cirrhosis, the recommended treatment regimen is sofosbuvir/velpatasvir for 12 weeks. This combination therapy has shown high efficacy across various HCV genotypes, including genotype 2, and is well-tolerated by patients.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Ledipasvir/sofosbuvir is highly effective in treating HCV genotype 1 infections but is not the first choice for genotype 2.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> Elbasvir/grazoprevir is primarily used for HCV genotype 1 and 4 infections, and thus not the optimal choice for genotype 2.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Sofosbuvir and ribavirin for 24 weeks is an older regimen that may be considered in certain contexts for genotype 2 but is less preferable due to the longer treatment duration and side effects associated with ribavirin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The efficacy of sofosbuvir/velpatasvir for 12 weeks helps&nbsp; in treating HCV genotype 2 infections. </span></span></span></p>",
      "correct_choice_id": 80798,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20211,
      "choices": [
        {
          "id": 80805,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alcoholic hepatitis</span></span></p>"
        },
        {
          "id": 80806,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-alcoholic fatty liver disease (NAFLD)</span></span></p>"
        },
        {
          "id": 80807,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Autoimmune hepatitis</span></span></p>"
        },
        {
          "id": 80808,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary biliary cholangitis</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old female presents with fatigue, jaundice, and abdominal discomfort for the past few weeks. Laboratory tests reveal elevated liver enzymes, hypergammaglobulinemia, and positive antinuclear antibodies (ANA) and anti-smooth muscle antibodies (ASMA). What is the most likely diagnosis based on these findings?</span></span></p>",
      "unique_key": "Q5013351",
      "question_audio": null,
      "question_video": null,
      "map_id": 20158,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Autoimmune hepatitis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presentation of fatigue, jaundice, elevated liver enzymes, hypergammaglobulinemia, and positive autoantibodies (ANA and ASMA) is highly suggestive of autoimmune hepatitis. This chronic inflammatory liver disease is characterized by immune-mediated hepatocellular injury.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Alcoholic hepatitis</span></strong><span style=\"font-size:12.0pt\">: While alcoholic hepatitis can present with similar symptoms, it is typically associated with a history of excessive alcohol consumption and may not have the characteristic autoantibodies seen in autoimmune hepatitis.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Non-alcoholic fatty liver disease (NAFLD)</span></strong><span style=\"font-size:12.0pt\">: NAFLD typically presents with elevated liver enzymes and fatty infiltration of the liver but lacks the characteristic autoimmune serological markers seen in autoimmune hepatitis.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Primary biliary cholangitis</span></strong><span style=\"font-size:12.0pt\">: Primary biliary cholangitis may present with similar symptoms, but it is characterized by the presence of anti-mitochondrial antibodies (AMA) and histological features of bile duct damage, which are not seen in autoimmune hepatitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation and laboratory findings of autoimmune hepatitis, includes elevated liver enzymes, hypergammaglobulinemia, and positive autoantibodies (ANA and ASMA).</span></span></span></p>",
      "correct_choice_id": 80807,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20213,
      "choices": [
        {
          "id": 80813,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corticosteroids</span></span></p>"
        },
        {
          "id": 80814,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ursodeoxycholic acid (UDCA)</span></span></p>"
        },
        {
          "id": 80815,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Azathioprine</span></span></p>"
        },
        {
          "id": 80816,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methotrexate</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the most appropriate initial treatment for autoimmune hepatitis ?</span></span></p>",
      "unique_key": "Q1503948",
      "question_audio": null,
      "question_video": null,
      "map_id": 20161,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Corticosteroids</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corticosteroids such as prednisone or prednisolone are the mainstay of treatment for autoimmune hepatitis. They suppress inflammation and reduce immune-mediated hepatocellular injury, leading to clinical improvement and normalization of liver enzymes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ursodeoxycholic acid</span></strong><span style=\"font-size:12.0pt\"> (UDCA): UDCA is used in primary biliary cholangitis but is not the first-line treatment for autoimmune hepatitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Azathioprine</span></strong><span style=\"font-size:12.0pt\">: Azathioprine is often used as a steroid-sparing agent in autoimmune hepatitis but is typically initiated after corticosteroids as maintenance therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Methotrexate</span></strong><span style=\"font-size:12.0pt\">: Methotrexate is not a first-line treatment for autoimmune hepatitis and is associated with potential hepatotoxicity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The initial treatment approach for autoimmune hepatitis, is the use of corticosteroids to suppress inflammation and reduce immune-mediated hepatocellular injury, helps in effectively managing the disease and improving patient outcomes.</span></span></p>",
      "correct_choice_id": 80813,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20214,
      "choices": [
        {
          "id": 80817,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alcoholic liver disease</span></span></p>"
        },
        {
          "id": 80818,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary biliary cholangitis (PBC)</span></span></p>"
        },
        {
          "id": 80819,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Autoimmune hepatitis</span></span></p>"
        },
        {
          "id": 80820,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-alcoholic fatty liver disease (NAFLD)</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 55-year-old female presents with fatigue, pruritus, and right upper quadrant abdominal pain. Laboratory tests show elevated alkaline phosphatase and positive anti-mitochondrial antibodies (AMA). Abdominal imaging reveals hepatomegaly and features suggestive of intrahepatic cholestasis. What is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q4180563",
      "question_audio": null,
      "question_video": null,
      "map_id": 20162,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Primary biliary cholangitis (PBC)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation of fatigue, pruritus, right upper quadrant abdominal pain, elevated alkaline phosphatase, positive anti-mitochondrial antibodies (AMA), and features of intrahepatic cholestasis on imaging is characteristic of primary biliary cholangitis (PBC).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Alcoholic liver disease</span></strong><span style=\"font-size:12.0pt\">: Alcoholic liver disease typically presents with a history of alcohol abuse and may have elevated liver enzymes but lacks the characteristic AMA positivity seen in PBC.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Autoimmune hepatitis</span></strong><span style=\"font-size:12.0pt\">: Autoimmune hepatitis may present with similar symptoms but is characterized by elevated transaminases and positive antinuclear antibodies (ANA) and anti-smooth muscle antibodies (ASMA), rather than AMA.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Non-alcoholic fatty liver disease</span></strong><span style=\"font-size:12.0pt\"> (NAFLD): NAFLD typically presents with features of metabolic syndrome and may have elevated liver enzymes, but it does not typically present with pruritus or positive AMA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation and laboratory findings of primary biliary cholangitis (PBC), includes pruritus, elevated alkaline phosphatase, and positive anti-mitochondrial antibodies (AMA).</span></span></span></p>",
      "correct_choice_id": 80818,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20215,
      "choices": [
        {
          "id": 80821,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ursodeoxycholic acid (UDCA)</span></span></p>"
        },
        {
          "id": 80822,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corticosteroids</span></span></p>"
        },
        {
          "id": 80823,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methotrexate</span></span></p>"
        },
        {
          "id": 80824,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Azathioprine</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the most appropriate initial pharmacological treatment for early-stage primary biliary cholangitis (PBC)?</span></span></p>",
      "unique_key": "Q7753798",
      "question_audio": null,
      "question_video": null,
      "map_id": 20163,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Ursodeoxycholic acid (UDCA)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Ursodeoxycholic acid (UDCA) is the first-line pharmacological treatment for primary biliary cholangitis (PBC). It improves liver function tests and slows disease progression by promoting bile flow and reducing liver inflammation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Corticosteroids</span></strong><span style=\"font-size:12.0pt\">: Corticosteroids are not first-line treatment for PBC and may be considered in certain cases of refractory disease or overlap syndromes.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Methotrexate</span></strong><span style=\"font-size:12.0pt\">: Methotrexate is not recommended for the treatment of PBC and is associated with potential hepatotoxicity.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Azathioprine</span></strong><span style=\"font-size:12.0pt\">: Azathioprine may be used as an adjunctive therapy in PBC but is not typically initiated as first-line treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></strong></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The initial pharmacological management of primary biliary cholangitis (PBC), includes the use of ursodeoxycholic acid (UDCA) to improve liver function and slow disease progression.</span></span></p>",
      "correct_choice_id": 80821,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20218,
      "choices": [
        {
          "id": 80833,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alcoholic liver disease</span></span></p>"
        },
        {
          "id": 80834,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary sclerosing cholangitis (PSC)</span></span></p>"
        },
        {
          "id": 80835,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Autoimmune hepatitis</span></span></p>"
        },
        {
          "id": 80836,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-alcoholic fatty liver disease (NAFLD)</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old male presents with fatigue, pruritus, and jaundice. Laboratory tests reveal elevated alkaline phosphatase and serum bilirubin levels. Imaging studies show multifocal strictures and dilatations of the intrahepatic and extrahepatic bile ducts. What is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q3230801",
      "question_audio": null,
      "question_video": null,
      "map_id": 20166,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Primary sclerosing cholangitis (PSC)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presentation of fatigue, pruritus, jaundice, elevated alkaline phosphatase, and imaging findings of multifocal strictures and dilatations of the intrahepatic and extrahepatic bile ducts is most consistent with primary sclerosing cholangitis (PSC). PSC is a chronic, progressive liver disease characterized by inflammation and fibrosis of the bile ducts, leading to bile duct strictures that can cause symptoms like jaundice and pruritus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Alcoholic liver disease typically presents with a history of significant alcohol consumption and can lead to a spectrum of liver abnormalities, including steatosis, alcoholic hepatitis, and cirrhosis, but it does not typically present with the specific bile duct changes seen in PSC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> Autoimmune hepatitis is characterized by inflammation of the liver due to an autoimmune response and is often associated with elevated transaminases and positive autoimmune markers, which are not the primary findings in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Non-alcoholic fatty liver disease (NAFLD) is associated with metabolic risk factors such as obesity, diabetes, and hyperlipidemia and primarily affects the liver parenchyma, leading to steatosis and potentially steatohepatitis, but it does not cause the bile duct abnormalities seen in PSC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation of fatigue, pruritus, jaundice, elevated alkaline phosphatase, and serum bilirubin levels, along with characteristic imaging findings of multifocal strictures and dilatations of bile ducts, is typical of primary sclerosing cholangitis (PSC).</span></span></span></p>",
      "correct_choice_id": 80834,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20219,
      "choices": [
        {
          "id": 80837,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Steatosis</span></span></p>"
        },
        {
          "id": 80838,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mallory-Denk bodies</span></span></p>"
        },
        {
          "id": 80839,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Granulomas</span></span></p>"
        },
        {
          "id": 80840,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Onion-skinning</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What histopathological feature is characteristic of primary sclerosing cholangitis (PSC) ?</span></span></p>",
      "unique_key": "Q4135459",
      "question_audio": null,
      "question_video": null,
      "map_id": 20167,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Onion-skinning</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Onion-skinning, which refers to the concentric layers of fibrosis surrounding bile ducts, is a characteristic histopathological feature of primary sclerosing cholangitis (PSC). This feature represents the progressive fibrosis that narrows the bile ducts, leading to their strictures and the clinical manifestations of PSC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-174600.jpg\" style=\"height:222px; width:300px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Steatosis, or the accumulation of fat within liver cells, is a feature more commonly associated with conditions like non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease, not PSC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong><span style=\"font-size:12.0pt\"> Mallory-Denk bodies are cytoplasmic inclusions found in liver cells, typically associated with alcoholic liver disease and not characteristic of PSC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> Granulomas are aggregates of macrophages and are more typically associated with conditions such as sarcoidosis or granulomatous hepatitis, not specifically characteristic of PSC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></strong></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Onion-skinning, characterized by concentric fibrosis and inflammation around bile ducts, is a characteristic histopathological feature of primary sclerosing cholangitis</span></span></p>",
      "correct_choice_id": 80840,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20220,
      "choices": [
        {
          "id": 80841,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Parkinson&#39;s Disease</span></span></p>"
        },
        {
          "id": 80842,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wilson Disease </span></span></p>"
        },
        {
          "id": 80843,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Juvenile Huntington&#39;s Disease </span></span></p>"
        },
        {
          "id": 80844,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Multiple Sclerosis</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 17-year-old male presents with worsening academic performance, behavioral changes, slowed movements, and a slight tremor. Ophthalmological examination shows the following finding. What is the most likely diagnosis? </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-174749.jpg\" style=\"height:152px; width:300px\" /></p>",
      "unique_key": "Q4055364",
      "question_audio": null,
      "question_video": null,
      "map_id": 20168,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Wilson Disease</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Wilson Disease is a genetic disorder that leads to copper accumulation in tissues, resulting in neurological symptoms and liver disease. The greenish-brown ring around the periphery of the corneas, known as the Kayser-Fleischer ring, is a classic finding in Wilson Disease. The presentation of worsening academic performance, behavioral changes, slowed movements, and tremor in a young patient is consistent with the neuropsychiatric manifestations of Wilson Disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Parkinson&#39;s Disease typically presents in older adults and is characterized by bradykinesia, resting tremor, rigidity, and postural instability, without the presence of Kayser-Fleischer rings.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> Juvenile Huntington&#39;s Disease can present with academic and behavioral changes and movement disorders but is distinguished by a family history of Huntington&#39;s Disease and the absence of Kayser-Fleischer rings.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Multiple Sclerosis is an autoimmune condition affecting the central nervous system and can present with a wide range of neurological symptoms, but it does not cause Kayser-Fleischer rings or copper accumulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational objective is to recognize the presentation and classic findings of Wilson Disease, particularly the presence of Kayser-Fleischer rings and a combination of hepatic and neuropsychiatric symptoms in a young patient.</span></span></span></p>",
      "correct_choice_id": 80842,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20221,
      "choices": [
        {
          "id": 80845,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hepatitis C infection</span></span></p>"
        },
        {
          "id": 80846,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Copper accumulation in Wilson Disease</span></span></p>"
        },
        {
          "id": 80847,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Iron overload in hemochromatosis </span></span></p>"
        },
        {
          "id": 80848,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bilirubin deposition in Dubin-Johnson syndrome</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the significance of the finding in the image?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-175158.jpg\" style=\"height:153px; width:300px\" /></span></span></p>",
      "unique_key": "Q4672281",
      "question_audio": null,
      "question_video": null,
      "map_id": 20169,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Copper accumulation in Wilson Disease</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presence of a greenish-brown discoloration of the cornea periphery, known as Kayser-Fleischer rings, is a significant finding indicative of copper accumulation in Wilson Disease. Wilson Disease is a genetic disorder characterized by excessive deposition of copper in the liver, brain, and other tissues, leading to liver dysfunction and neuropsychiatric symptoms. The Kayser-Fleischer rings are caused by copper deposition in the corneal limbus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Hepatitis C infection can lead to liver dysfunction, but it does not cause Kayser-Fleischer rings or copper accumulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C</span></strong><span style=\"font-size:12.0pt\">. Iron overload occurs in hemochromatosis, a different condition characterized by excessive iron deposition in the body, but it does not lead to Kayser-Fleischer rings.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Bilirubin deposition occurs in conditions like Dubin-Johnson syndrome, which can lead to liver dysfunction and jaundice, but not Kayser-Fleischer rings.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Kayser-Fleischer rings, a greenish-brown discoloration of the cornea periphery, is indicative of copper accumulation in Wilson Disease, which can cause liver dysfunction and neuropsychiatric symptoms.</span></span></span></p>",
      "correct_choice_id": 80846,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20222,
      "choices": [
        {
          "id": 80849,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum ceruloplasmin levels </span></span></p>"
        },
        {
          "id": 80850,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum copper levels </span></span></p>"
        },
        {
          "id": 80851,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liver biopsy </span></span></p>"
        },
        {
          "id": 80852,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Genetic testing for ATP7B mutations</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following diagnostic tests is most appropriate for confirming Wilson&rsquo;s disease? </span></span></p>",
      "unique_key": "Q4164418",
      "question_audio": null,
      "question_video": null,
      "map_id": 20170,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">D) Genetic testing for ATP7B mutations</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Genetic testing for ATP7B mutations is the most definitive diagnostic test for confirming Wilson Disease, as it directly identifies mutations in the gene responsible for copper transport. Confirming the presence of ATP7B mutations establishes the genetic basis of the disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Serum ceruloplasmin levels are often low in Wilson Disease, but this finding is not specific and can be seen in other conditions or in carriers of the disease without clinical manifestations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong><span style=\"font-size:12.0pt\"> Serum copper levels can be elevated in Wilson Disease, but they can also be normal or low, making this test less reliable for diagnosis. Free copper levels (non-ceruloplasmin bound copper) can be more indicative but still lack the specificity of genetic testing.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> Liver biopsy can demonstrate copper accumulation and liver damage, and it can be useful in cases where the diagnosis is unclear. However, it is invasive and carries risks, making genetic testing a more definitive and less invasive option when available.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Genetic testing for ATP7B mutations is the most definitive method for confirming a diagnosis of Wilson Disease, that directly identifies the genetic cause of the disorder.</span></span></p>",
      "correct_choice_id": 80852,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20224,
      "choices": [
        {
          "id": 80857,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Child-Pugh Score </span></span></p>"
        },
        {
          "id": 80858,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MELD Score </span></span></p>"
        },
        {
          "id": 80859,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nazer Score </span></span></p>"
        },
        {
          "id": 80860,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ranson&#39;s Criteria</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What scoring system is commonly used for the initial assessment and diagnosis of Wilson Disease? </span></span></p>",
      "unique_key": "Q1306022",
      "question_audio": null,
      "question_video": null,
      "map_id": 20172,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Nazer Score</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Nazer Score is a scoring system specifically designed for the initial assessment and diagnosis of Wilson Disease. It takes into account various clinical, biochemical, and histological parameters, including neurological symptoms, Kayser-Fleischer rings, serum ceruloplasmin, liver histology, and urinary copper excretion, to help in the diagnosis of Wilson Disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A</span></strong><span style=\"font-size:12.0pt\">. The Child-Pugh Score is used to assess the prognosis of chronic liver disease, mainly cirrhosis, and to determine the required strength of treatment and the need for liver transplantation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B</span></strong><span style=\"font-size:12.0pt\">. The MELD Score (Model for End-Stage Liver Disease) is used to prioritize patients for liver transplantation, based on the severity of chronic liver disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Ranson&#39;s Criteria are used to assess the severity of acute pancreatitis and predict its outcome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The Nazer Score is a scoring system used for the initial assessment and diagnosis of Wilson Disease, incorporating clinical, biochemical, and histological parameters relevant to the disease.</span></span></span></p>",
      "correct_choice_id": 80859,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53941,
      "choices": [
        {
          "id": 215233,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Iron chelation therapy </span></span></p>"
        },
        {
          "id": 215234,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Copper chelation therapy </span></span></p>"
        },
        {
          "id": 215235,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corticosteroids </span></span></p>"
        },
        {
          "id": 215236,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ursodeoxycholic acid (UDCA)</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the mainstay of treatment for Wilson&rsquo;s disease? </span></span></p>",
      "unique_key": "Q6237460",
      "question_audio": null,
      "question_video": null,
      "map_id": 25535,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Copper chelation therapy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Copper chelation therapy is the mainstay of treatment for Wilson Disease. This treatment approach involves using medications such as penicillamine or trientine to bind copper and facilitate its excretion from the body, thereby reducing copper accumulation in tissues.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Iron chelation therapy is used to treat conditions involving iron overload, such as hemochromatosis, not Wilson Disease, which involves copper accumulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> Corticosteroids are not a primary treatment for Wilson Disease; they are more commonly used in conditions involving inflammation or autoimmune processes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Ursodeoxycholic acid (UDCA) is used to improve liver function in certain liver diseases, such as primary biliary cirrhosis, but it is not a mainstay of treatment for Wilson Disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In copper chelation therapy, using agents such as penicillamine or trientine, is the mainstay of treatment for Wilson Disease to reduce copper accumulation in the body.</span></span></span></p>",
      "correct_choice_id": 215234,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53942,
      "choices": [
        {
          "id": 215237,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic obstructive pulmonary disease (COPD)</span></span></p>"
        },
        {
          "id": 215238,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Asthma</span></span></p>"
        },
        {
          "id": 215239,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha-1 antitrypsin (AAT) deficiency</span></span></p>"
        },
        {
          "id": 215240,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cystic fibrosis</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old non-smoking male presents with exertional dyspnea and recurrent respiratory infections. Pulmonary function tests reveal airflow obstruction that does not significantly improve with bronchodilators. What is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q5071366",
      "question_audio": null,
      "question_video": null,
      "map_id": 25536,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Alpha-1 antitrypsin (AAT) deficiency</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presentation of airflow obstruction in a non-smoking individual, particularly with a history of recurrent respiratory infections and a lack of response to bronchodilators, is highly suggestive of alpha-1 antitrypsin (AAT) deficiency, an inherited disorder predisposing to early-onset emphysema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chronic obstructive pulmonary disease (COPD):</span></strong><span style=\"font-size:12.0pt\"> While COPD may present similarly to AAT deficiency, the lack of significant smoking history and the presence of recurrent respiratory infections suggest an alternative diagnosis such as AAT deficiency.</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option B. Asthma</strong>: Asthma typically presents with reversible airflow obstruction and bronchial hyperresponsiveness, which may improve with bronchodilators, unlike the non-responsiveness seen in this case.</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option D. Cystic fibrosis</strong>: Cystic fibrosis often presents with recurrent respiratory infections and obstructive lung disease but is associated with characteristic features such as pancreatic insufficiency and elevated sweat chloride levels, which are absent in AAT deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation of AAT deficiency, includes early-onset emphysema in non-smokers and a lack of response to bronchodilators.</span></span></span></p>",
      "correct_choice_id": 215239,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53944,
      "choices": [
        {
          "id": 215245,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha-1 antitrypsin (AAT) level measurement</span></span></p>"
        },
        {
          "id": 215246,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chest X-ray</span></span></p>"
        },
        {
          "id": 215247,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High-resolution computed tomography (HRCT) scan of the chest</span></span></p>"
        },
        {
          "id": 215248,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Genetic testing for cystic fibrosis</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old male presents with a family history of early-onset emphysema. Pulmonary function tests reveal airflow obstruction that does not improve significantly with bronchodilators. What is the most appropriate initial diagnostic test?</span></span></span></p>",
      "unique_key": "Q1491669",
      "question_audio": null,
      "question_video": null,
      "map_id": 25538,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Alpha-1 antitrypsin (AAT) level measurement</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Measurement of alpha-1 antitrypsin (AAT) levels is the most appropriate initial diagnostic test for suspected AAT deficiency. Low serum levels of AAT confirm the diagnosis, particularly in individuals with a family history of early-onset emphysema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Chest X-ray</span></strong><span style=\"font-size:12.0pt\">: While chest X-ray may reveal findings suggestive of emphysema, it is not specific for AAT deficiency and may not establish a definitive diagnosis.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. High-resolution computed tomography (HRCT) scan of the chest</span></strong><span style=\"font-size:12.0pt\">: HRCT may show characteristic changes of emphysema, but it is not specific for AAT deficiency and may not be necessary as an initial diagnostic test.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Genetic testing for cystic fibrosis</span></strong><span style=\"font-size:12.0pt\">: Genetic testing for cystic fibrosis is not indicated in the absence of clinical features suggestive of the condition, such as pancreatic insufficiency and elevated sweat chloride levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alpha-1 antitrypsin (AAT) level measurement is the initial diagnostic test for suspected AAT deficiency helps in establishing a timely and accurate diagnosis to guide management decisions.</span></span></span></p>",
      "correct_choice_id": 215245,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53945,
      "choices": [
        {
          "id": 215249,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Long-acting beta-agonists (LABAs)</span></span></p>"
        },
        {
          "id": 215250,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhaled corticosteroids</span></span></p>"
        },
        {
          "id": 215251,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha-1 antitrypsin augmentation therapy</span></span></p>"
        },
        {
          "id": 215252,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oxygen therapy</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">What is the most appropriate treatment to slow disease progression in emphysema due to alpha-1 antitrypsin (AAT) deficiency?</span></span></span></p>",
      "unique_key": "Q8515571",
      "question_audio": null,
      "question_video": null,
      "map_id": 25539,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) Alpha-1 antitrypsin augmentation therapy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Alpha-1 antitrypsin (AAT) augmentation therapy, consisting of intravenous infusions of purified AAT protein, is the most appropriate treatment to slow disease progression and prevent further lung damage in patients with AAT deficiency and emphysema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Long-acting beta-agonists (LABAs)</span></strong><span style=\"font-size:12.0pt\">: LABAs may provide symptomatic relief but do not address the underlying deficiency of AAT and do not slow disease progression.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Inhaled corticosteroids</span></strong><span style=\"font-size:12.0pt\">: Inhaled corticosteroids may be used in patients with AAT deficiency and asthma or chronic bronchitis but are not effective in slowing the progression of emphysema.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Oxygen therapy</span></strong><span style=\"font-size:12.0pt\">: Oxygen therapy is used for symptomatic relief in patients with advanced emphysema and hypoxemia but does not address the underlying deficiency of AAT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></span></u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></strong></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha-1 antitrypsin (AAT) augmentation therapy helps in slowing disease progression in patients with AAT deficiency and emphysema.</span></span></p>",
      "correct_choice_id": 215251,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53947,
      "choices": [
        {
          "id": 215257,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Wilson Disease</span></span></p>"
        },
        {
          "id": 215258,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemochromatosis</span></span></p>"
        },
        {
          "id": 215259,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha1 antitrypsin (A1AT) deficiency</span></span></p>"
        },
        {
          "id": 215260,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Systemic lupus erythematosus (SLE)</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old male presents with fatigue, weakness, and joint pain. Physical examination reveals skin pigmentation as in the image below and hepatomegaly. Laboratory tests show elevated serum ferritin levels and increased transferrin saturation. What is the most likely diagnosis?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-180615.jpg\" style=\"height:205px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q8719056",
      "question_audio": null,
      "question_video": null,
      "map_id": 25541,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Hemochromatosis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The presentation of fatigue, weakness, joint pain, bronze skin pigmentation, hepatomegaly, elevated serum ferritin levels, and increased transferrin saturation is highly suggestive of hemochromatosis. Hemochromatosis is a genetic disorder characterized by excessive absorption and accumulation of iron in various organs, leading to their dysfunction.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Wilson Disease involves copper accumulation and typically presents with liver dysfunction and neuropsychiatric symptoms, not primarily iron overload symptoms.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> Alpha1 antitrypsin (A1AT) deficiency is a genetic disorder that can lead to liver disease and lung disease, but it is not associated with iron overload or the specific constellation of symptoms described.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect multiple organ systems and cause a wide range of symptoms, but it does not cause iron overload or the specific features described here.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical features of hemochromatosis, includes fatigue, bronze skin pigmentation, hepatomegaly, and elevated serum ferritin levels.</span></span></span></p>",
      "correct_choice_id": 215258,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53950,
      "choices": [
        {
          "id": 215269,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liver biopsy</span></span></p>"
        },
        {
          "id": 215270,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Genetic testing for HFE mutations</span></span></p>"
        },
        {
          "id": 215271,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum ceruloplasmin levels</span></span></p>"
        },
        {
          "id": 215272,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Abdominal ultrasound</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What diagnostic test is most appropriate for confirming the suspected diagnosis of hemochromatosis?</span></span></p>",
      "unique_key": "Q9006137",
      "question_audio": null,
      "question_video": null,
      "map_id": 25544,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">B) Genetic testing for HFE mutations</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Genetic testing for HFE mutations is the most appropriate diagnostic test for confirming the suspected diagnosis of hemochromatosis. The HFE gene mutations, particularly C282Y and H63D, are commonly associated with hereditary hemochromatosis, a condition characterized by excessive iron absorption and accumulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.</span></strong><span style=\"font-size:12.0pt\"> Liver biopsy can be used to assess the degree of liver damage and iron accumulation but is not the first-line test for diagnosing hemochromatosis due to its invasiveness.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> Serum ceruloplasmin levels are used in the evaluation of Wilson Disease, which involves copper metabolism, not iron.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Abdominal ultrasound can evaluate liver size and structure but is not specific for diagnosing hemochromatosis. It cannot directly detect iron overload.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Genetic testing for HFE mutations is the most direct and specific diagnostic test for confirming hereditary hemochromatosis, given its association with specific gene mutations.</span></span></span></p>",
      "correct_choice_id": 215270,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53952,
      "choices": [
        {
          "id": 215277,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phlebotomy</span></span></p>"
        },
        {
          "id": 215278,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Iron chelation therapy</span></span></p>"
        },
        {
          "id": 215279,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liver transplantation</span></span></p>"
        },
        {
          "id": 215280,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Erythropoiesis-stimulating agents</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">What is the mainstay of treatment for reducing iron overload in hemochromatosis?</span></span></span></p>",
      "unique_key": "Q6101677",
      "question_audio": null,
      "question_video": null,
      "map_id": 25546,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">A) Phlebotomy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Phlebotomy, or therapeutic blood removal, is the mainstay of treatment for reducing iron overload in patients with hemochromatosis. Regular phlebotomy sessions help to decrease excess iron stores by removing blood, which contains iron, thereby reducing the total body iron burden.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong><span style=\"font-size:12.0pt\"> Iron chelation therapy is used primarily in patients who cannot undergo phlebotomy, such as those with anemia or heart complications, or in conditions of iron overload from repeated blood transfusions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> Liver transplantation may be considered in advanced cases of hemochromatosis with severe liver damage, but it is not a treatment for iron overload per se.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.</span></strong><span style=\"font-size:12.0pt\"> Erythropoiesis-stimulating agents are used to treat anemia, particularly in chronic kidney disease, and do not directly reduce iron overload.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Phlebotomy is the mainstay of treatment for reducing iron overload in patients with hemochromatosis, effectively lowering the total body iron burden through regular removal of blood.</span></span></span></p>",
      "correct_choice_id": 215277,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}